The agreement provides Novotech with the rights to sell in most Middle Eastern countries, all North African countries, India, Pakistan and certain other Asian countries. Sales will be
UK-based Synexus has achieved the first phase of its South African expansion programme. Earlier in October 2008, Synexus announced its intention to double its clinical trial capacity in
Germany-based Merck has opened a new Cosmetic Technology Center (CTC) at its Darmstadt site. The company said that in new laboratories and seminar rooms, customers now have the
Bayer Diabetes Care has introduced two new vibrant colors of BREEZE2 blood glucose meters; Pink and Purple. The company said that the BREEZE2 new color meters will have
Evotec has entered into a research agreement with Biogen Idec. Under the research agreement, Evotec will screen a target selected by Biogen Idec with the option to add
Solvay Biologicals has completed the validation for its cell-based production facility following a successful inspection by the Dutch authorities. The company said that the 3,900m2 facility in Weesp
XOMA and Arana Therapeutics have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite
Cempra Pharmaceuticals (Cempra) has initiated phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). Reportedly, the first of two pivotal trials
NephroGenex has completed patient enrollment in its phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2
Regado Biosciences ( Regado) has reported enrollment of the first patient in a phase 2b, randomised, partially-blinded, multi-center, active-controlled, dose-ranging study of its product candidate, the REG1 anticoagulation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.